#ADCT

4 days ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026. LAUSANNE, Switzerland, March 10, 2026/ PRNewswire/-- ADC Therapeutics SA, a commercial-stage global leader and pioneer in the field of antibody drug conjugates, today reported financial results for the fourth quarter and full year...

#ADCT ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

ADC Therapeutics hands 135K options to 3 new hires over 4 years Equity grants to 3 new hires total 135,000 options under ADC Therapeutics’ Inducement Plan, vesting over four years under NYSE Rule 303A.08.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Trade Alerts, Wednesday January 14, 2026 – Crystal Equity Research

Small-cap stocks with declining money flow, Wed Jan 14th - #COSM #BLZR #RVP #ZJYL #SHEN #PAYS #MCRI #GABC #FACT #CENTA #BEEM #ARTV #MEG #BOC #ADCT - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Pomerantz Law Firm Launches Investigation into ADC Therapeutics for Investors' Claims Pomerantz LLP is investigating allegations of potential securities fraud involving ADC Therapeutics, seeking investors to join the inquiry following troubling clinical trial results.

Pomerantz Law Firm Launches Investigation into ADC Therapeutics for Investors' Claims #USA #New_York #Pomerantz_LLP #ADC_Therapeutics #ADCT

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Wed Dec 3rd - #ARTL #DEVS #IMRN #LOT #WOK #VS #SONN #POLE #OMDA #IPWR #HCMA #CLNN #BWIN #ACHC #ADCT - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.

#ADCT #ADCT ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.

#ADCT #ADCT ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

ADC Therapeutics Announces $60 Million Private Placement ADC Therapeutics (NYSE: ADCT) announced a $60.0 million PIPE financing on October 13, 2025, selling 11.3 million common shares at $4.00 each and pre-funded warrants to purchase 3.8 million shares at $3.90 each.The PIPE is led by TCGX with participation from Redmile Group and others and is expected to close on October 27, 2025, subject to customary conditions. Net proceeds are estimated at $57.6 million after fees. The company reported Q3 2025 ZYNLONTA net product revenues of $15.8 million and $234.7 million cash on hand as of September 30, 2025, which would rise to approximately $292.3 million after the PIPE.

#ADCT #ADCT ADC Therapeutics Announces $60 Million Private Placement

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

Buhane Information Technologies

@buhane.com.tr

5 months ago

NVIDIA NV-Tesseract-AD: Revolutionizing Anomaly Detection with Advanced Techniques Discover how NVIDIA NV-Tesseract-AD is transforming anomaly detection through cutting-edge AI architectures, enabling high-speed, accurate anomaly identification across diverse industries.

NVIDIA NV-Tesseract-AD: Revolutionizing Anomaly Detection with Advanced Techniques Redefining the Landscape of Anomaly Detection with NV-Tesseract-AD The demands on anomaly detection systems have.... @cosmicmeta.ai #ADCT

https://u2m.io/wEJbeTLp

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

29,700 Stock Options: ADC Therapeutics Awards Inducement Grants with 4-Year Vesting Schedule Biotech leader ADC Therapeutics grants 29,700 stock options to two new employees under NYSE Rule 303A.08. Options vest 25% first year, followed by monthly installments over 4 years.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update ADC Therapeutics (NYSE:ADCT) reported Q2 2025 financial results and operational updates, highlighting significant progress in their ZYNLONTA® clinical programs. The company's LOTIS-7 trial showed impressive results with 93.3% overall response rate and 86.7% complete response rate in combination with glofitamab for r/r DLBCL patients.Key financial developments include a $100 million PIPE financing, extending cash runway into 2028, and Q2 2025 net product revenues of $18.1 million. The company reported a net loss of $56.6 million ($0.50 per share). A strategic restructuring plan was announced, reducing global workforce by 30% and discontinuing early development efforts in solid tumors to focus on ZYNLONTA.The LOTIS-5 Phase 3 trial is expected to reach PFS events by end-2025, with potential sBLA submission in H1 2026. The company's cash position stands at $264.6 million as of June 30, 2025.

#ADCT ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

ADC Therapeutics Awards Major Stock Options Package: 127,000 Shares for Key Biotech Talent Acquisition Biotech leader grants equity incentives worth 127,000 shares with 4-year vesting schedule. Discover how ADC Therapeutics attracts top talent in antibody drug development.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

ADC Therapeutics Awards Strategic Stock Options Package Worth 17,000 Shares to Attract Top Talent Leading ADC developer strengthens team with new hire compensation package featuring 4-year vesting schedule. See full grant details and strategic implications.

#ADCT ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

ADC Therapeutics Raises $100M in Strategic Pivot: Cuts Workforce 30%, Doubles Down on ZYNLONTA Development $100M private placement fuels ZYNLONTA development while 30% workforce reduction streamlines operations. See how this biotech's strategic transformation unfolds.

#ADCT ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with glofitamab for relapsed/refractory DLBCL patients. The combination demonstrated remarkable efficacy with a 93.3% overall response rate and 86.7% complete response rate among 30 evaluable patients. Notably, 25 of 26 patients achieving complete response maintained it at data cutoff. The treatment showed a manageable safety profile across 41 safety-evaluable patients, with main grade 3+ adverse events including neutropenia (24.4%) and anemia (9.8%). Based on these promising results, the company is expanding the trial enrollment to 100 patients at the 150 µg/kg dose level.

#ADCT ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

ADC Pioneer Awards Strategic Stock Options Package to Secure Top Industry Talent Leading ADC developer strengthens team with equity incentives for two strategic hires. See detailed vesting schedule and compensation strategy. Get insights.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

ADC Therapeutics Reports Breakthrough 95.5% Response Rate in Cancer Trial, Extends Cash Runway to 2026 New LOTIS-7 trial data reveals exceptional 90.9% complete response rate for ZYNLONTA combination therapy. Q1 results show strong financial position. See full details.

#ADCT ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Breakthrough Cancer Drug Shows 100% Tumor Response in Ovarian, Lung Cancer Models: AACR 2025 Data Reveals Latest preclinical data reveals potent antitumor activity for three novel cancer-fighting ADCs. Strong efficacy in multiple cancer types with excellent safety profile. See full results.

#ADCT ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

ADC Therapeutics Strengthens Team with Major Equity Incentive Package Strategic stock options granted to key new hires with 4-year vesting schedule. Discover how ADC Therapeutics aims to retain top talent. Full details inside.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update ADC Therapeutics (NYSE: ADCT) reported its Q4 and full year 2024 financial results. The company achieved significant milestones in its ZYNLONTA® clinical trials, with the LOTIS-7 Phase 1b trial showing 94% best ORR and 72% CR rate in combination with glofitamab. The LOTIS-5 Phase 3 confirmatory trial completed enrollment with data expected in late 2025.Financial highlights include Q4 2024 net product revenues of $16.4M and full-year revenues of $69.3M from ZYNLONTA®. The company reported a Q4 net loss of $30.7M ($0.29 per share) and full-year net loss of $157.8M ($1.62 per share). Cash position stands at $250.9M as of December 31, 2024, providing runway into second half of 2026.Operating expenses showed improvement with reduced R&D ($109.6M), S&M ($44.0M), and G&A ($41.9M) expenses compared to 2023.

#ADCT ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Game-Changing Cancer Drugs: ADC Therapeutics Unveils 3 New Targeted Therapies at AACR 2025 Latest preclinical data reveals promising ADCs targeting ovarian, lung, prostate, and blood cancers. Novel drug candidates show potential for precision oncology treatment.

#ADCT ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Strategic Stock Options Grant: ADC Therapeutics Secures Top Talent with 26.8K Share Package ADC Therapeutics grants 26,800 stock options to three new employees with four-year vesting schedule, reinforcing commitment to attract and retain key talent through equity incentives.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

ADC Therapeutics Grants Inducement Stock Options to New Employees in Retention Push ADC Therapeutics awards 20,000 common shares in stock options to two new hires, featuring four-year vesting schedule under NYSE employment inducement exemption.

#ADCT ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

ADC Therapeutics Completes Enrollment in Pivotal ZYNLONTA Lymphoma Trial with 80% Response Rate ADC Therapeutics achieves milestone in Phase 3 LOTIS-5 trial for ZYNLONTA-rituximab combo in DLBCL treatment, showing promising early results for lymphoma patients.

#ADCT ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

www.stocktitan.net/news/ADCT/adc-therapeuti...

0 0 0 0